NRROS and neoplasm: Taken together, LRRC33 or LRRC33-pro-TGF-β1 complex is a potential myeloid cell specific target to regulate TGF-β1 function in cancer cells and tumor microenvironment for non-genomic based therapy of AML and other myeloid cell malignancy in a broader context.